TransCode Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 4.82 million compared to USD 3.47 million a year ago. Basic loss per share from continuing operations was USD 264 compared to USD 216 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.44 USD | +15.20% | +78.53% | -78.16% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-78.16% | 7.64M | |
+9.99% | 114B | |
+12.01% | 107B | |
-3.07% | 22.22B | |
-0.67% | 21.28B | |
-4.64% | 18.8B | |
-6.90% | 17.51B | |
-39.36% | 17.17B | |
+5.82% | 14.14B | |
+33.05% | 12.2B |
- Stock Market
- Equities
- RNAZ Stock
- News TransCode Therapeutics, Inc.
- TransCode Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023